Key result
Among patients chronically treated with an ACEi or ARB for at least 2 years, 16.1% developed new-onset microalbuminuria, which predicted future cardiovascular events.
Population
1,433 patients arriving in a hospital-based Hypertension Unit, previously treated for at least 2 years with…
Design
Cohort
Authors
Loading...
New microalbuminuria despite chronic ACEi/ARB may signal higher CV risk; leaves open whether intensified therapy improves outcomes.
Cohort (n=1,433)
No
A significant proportion of hypertensive patients develop de-novo microalbuminuria despite chronic, adequate-dose RAAS suppression, indicating a potential need for therapy reappraisal.
Cerezo et al. (2011) conducted a cohort in Hypertension (n=1,433). Chronic ACEi or ARB therapy was evaluated on New-onset microalbuminuria. Among patients chronically treated with an ACEi or ARB for at least 2 years, 16.1% developed new-onset microalbuminuria, which predicted future cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: